{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:54:54Z","timestamp":1760316894065,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.schres.2021.07.003","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T08:24:54Z","timestamp":1625732694000},"page":"5-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The role of antipsychotics against COVID-19: A topic for debate"],"prefix":"10.1016","volume":"235","author":[{"given":"M.","family":"Canal-Rivero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Catal\u00e1n-Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rubio-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Garrido-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ruiz-Veguilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.E.","family":"Mart\u00edn-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arias-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Est\u00e9vez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2021.07.003_bb0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2021.02.002","article-title":"Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: a retrospective epidemiological study in a representative Spanish population","volume":"229","author":"Canal-Rivero","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.07.003_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpsm.2020.04.010","article-title":"Mental health and the SARS-CoV-2 pandemic","volume":"13","author":"Crespo-Facorro","year":"2020","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.schres.2021.07.003_bb0015","doi-asserted-by":"crossref","first-page":"646701","DOI":"10.3389\/fphar.2021.646701","article-title":"Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis","volume":"12","author":"Crespo-Facorro","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.schres.2021.07.003_bb0020","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00213-016-4422-7","article-title":"Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study","volume":"233","author":"Morl\u00e1n-Coarasa","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2021.07.003_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-020-05716-4","article-title":"Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review","volume":"238","author":"Plasencia-Garc\u00eda","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2021.07.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpsm.2020.04.004","article-title":"Psychiatry in the aftermath of COVID-19","volume":"13","author":"Vieta","year":"2020","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.schres.2021.07.003_bb0035","first-page":"108","article-title":"Letter to the editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease","author":"Zheng","year":"2020","journal-title":"Metab. Clin. Exp."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421002565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421002565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:46Z","timestamp":1760298106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421002565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":7,"alternative-id":["S0920996421002565"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2021.07.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of antipsychotics against COVID-19: A topic for debate","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2021.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}